Table 5. Filarial antigenemia and Bm14 antibody rates in subjects with microfilaremia before and after mass drug administration (MDA).
| CFA (%) | Bm14 (%) | |
| Pre-MDA-B | 98/104 (94.2) | 80/104 (76.9) |
| MDA-1 | 56/58 (96.6) | 41/58 (70.7) |
| MDA-2 | 21/23 (91.3) | 18/23 (78.3) |
| MDA-3 | 6/7 (85.7) | 6/7 (85.7) |
Data shown are the number of subjects with positive tests and the number of Mf-positive subjects tested (% positive) before the first round of MDA and approximately 12 months after each round of MDA.
Abbreviations: Mf, microfilaremia; CFA, circulating filarial antigenemia; Bm14, IgG4 antibodies to recombinant filarial antigen Bm14.